BLUEJET Blue Jet Healthcare Q3 FY25 results (Oct–Dec 2024) and concall
Blue Jet Healthcare delivered a record-breaking Q3 FY25, driven by strong execution and the full operationalization of new capacities in Unit 2. The company reported significant growth across revenue, EBITDA, and PAT, with pharmaceutical intermediates being a key driver. Management expressed confidence in sustained growth, supported by a robust order book, ongoing R&D investments, and strategic capacity expansions, including an upward revision in annual EBITDA margin expectations.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 |
|---|---|---|
| Revenue | 208 | 318 |
| EBITDA | 69 | 124 |
| Net profit | 58 | 99 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
